Table 4 |
||||
|
Total cumulative dosing and treatment duration |
||||
|
Safety population |
AC-1202 n = 86 |
Placebo n = 66 |
||
|
|
||||
|
Total Cumulative Dose |
||||
|
Mean dose (grams) ± SD |
3555.00 ± 1883.89 |
4424.55 ± 1326.78 |
||
|
Median |
4515 |
4965 |
||
|
Median percent of intended dose |
86.99% |
95.66% |
||
|
(Range) |
(30, 5460) |
(150, 5550) |
||
|
|
||||
|
Treatment Duration (days) |
||||
|
N* |
82 |
66 |
||
|
Mean ± SD |
71.66 ± 31.08 |
83.91 ± 18.26 |
||
|
Median |
90.0 |
91.0 |
||
|
(Range) |
(1, 101) |
(5, 103) |
||
|
|
||||
|
Genotyped population |
APOE4(-) n = 36 |
APOE4(+) n = 39 |
APOE4(-) n = 27 |
APOE4(+) n = 33 |
|
|
||||
|
Total Cumulative Dose |
||||
|
Mean dose (grams) |
3049.17 |
4015.38 |
4382.22 |
4375.45 |
|
± SD |
± 2076.41 |
± 1531.93 |
1398.93 |
± 1386.91 |
|
Median |
3780 |
4740 |
4950 |
4980 |
|
Median percent of intended dose |
72.8% |
91.3% |
95.4% |
95.6% |
|
Range (grams) |
30 – 5430 |
30 – 5460 |
240 – 5490 |
150 – 5550 |
|
|
||||
|
Treatment Duration (days) |
||||
|
N* |
34 |
38 |
27 |
33 |
|
Mean |
64.1 |
77.8 |
87.1 |
80.3 |
|
± SD |
± 36.44 |
± 24.3 |
± 11.2 |
+23.3 |
|
Median |
88.0 |
90.0 |
91.0 |
91.0 |
|
Range (days) |
3 – 96 |
1 – 101 |
56 – 103 |
5 – 100 |
|
|
||||
|
*Treatment duration was unknown for 4 AC-1202 subjects for whom last date of study medication was not recorded |
||||
|
Henderson et al. Nutrition & Metabolism 2009 6:31 doi:10.1186/1743-7075-6-31 |
||||
